midostaurin (Rydapt)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

* with food

Capsules: 25 mg

Adverse effects

Drug interactions

  • strong CYP3A4 Inhibitors may increase exposure to midostaurin & its active metabolite

Mechanism of action

More general terms

References

  1. Gotlib J, Kluin-Nelemans HC, George TI et al Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. N Engl J Med. 2016 Jun 30;374(26):2530-41. PMID: https://www.ncbi.nlm.nih.gov/pubmed/27355533 Free Article
  2. O'Neil A, Klil-Drori AJ. AML: FLT3 Inhibitor Shows 'Robust' Activity as Frontline Therapy - Overall response rate 100% in patients with FLT3- mutated disease in early research. MedPage Today. Jan 17, 2018 https://www.medpagetoday.com/reading-room/asco/hematologic-malignancies/70559
  3. RYDAPT prescribing information https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/rydapt.pdf

Database